Keywords: Lung, Lung
Motivation: Drug-induced interstitial lung disease (DI-ILD) is particularly difficult to diagnose. We sought to assess whether MR imaging biomarkers can provide new insights into the changes caused by bleomycin.
Goal(s): To evaluate if hyperpolarised xenon and dynamic contrast-enhanced MRI can better describe pathophysiological changes from bleomycin chemotherapy.
Approach: A single-centre prospective study with imaging: prior to chemotherapy, 1-6 weeks post cycle 1, 8-14 weeks post cycle 3 OR 4 and 24-28 weeks following completion of chemotherapy.
Results: Eleven patients were recruited. RBC:M ratio and PBV changes suggesting inflammatory rather than fibrotic alterations in this cohort of patients.
Impact: Improved early diagnosis of drug-induced lung toxicity using a combination of structural and functional MRI may directly influence how inflammatory and fibrotic ILD is managed, particularly in patients undergoing novel therapies.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords